# MK0429 Study in Prostate Cancer Patients With Metastatic Bone Disease (0429-011)

> **NCT00302471** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 29 (actual)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **DRUG:** Comparator: MK0429
- **DRUG:** Comparator: MK0429
- **DRUG:** Comparator: MK0429
- **DRUG:** Comparator: MK0429

## Key facts

- **NCT ID:** NCT00302471
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2007-10
- **Final completion:** 2007-10
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2015-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00302471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00302471, "MK0429 Study in Prostate Cancer Patients With Metastatic Bone Disease (0429-011)". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT00302471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*